Search Results | Clinical Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

Adi Diab, Omid Hamid, John A. Thompson, Willeke Ros, Ferry A.L.M. Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J. Klempner, Bishu Ganguly, Catherine Fleener, Xiao Wang, Tenshang Joh, Ken Liao, Shahram Salek-Ardakani, Carrie Turich Taylor, Jeffrey Chou, Anthony B. El-Khoueiry

Clin Cancer Res (2022) 28 (1): 71–83.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-0845

Published: 05 January 2022

View article

Includes: Supplementary data

Journal Articles

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander D. Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, Georgina V. Long

Clin Cancer Res (2020) 26 (19): 5086–5091.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-0177

Published: 01 October 2020

View article

Includes: Supplementary data

Journal Articles

Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas

John A. Thompson, Robert J. Motzer, Ana M. Molina, Toni K. Choueiri, Elisabeth I. Heath, Bruce G. Redman, Randeep S. Sangha, D. Scott Ernst, Roberto Pili, Stella K. Kim, Leonard Reyno, Aya Wiseman, Fabio Trave, Banmeet Anand, Karen Morrison, Fernando Doñate, Christian K. Kollmannsberger

Clin Cancer Res (2018) 24 (18): 4399–4406.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-0481

Published: 14 September 2018

View article

Includes: Supplementary data

Journal Articles

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas

Clin Cancer Res (2018) 24 (8): 1805–1815.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-3436

Published: 12 April 2018

View article

Includes: Supplementary data

Journal Articles

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

Jeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, Manish R. Patel, Holbrook E.K. Kohrt, John A. Thompson, Paul M. Sondel, Heather A. Wakelee, Mary L. Disis, Judith C. Kaiser, Martin A. Cheever, Howard Streicher, Steven P. Creekmore, Thomas A. Waldmann, Kevin C. Conlon

Clin Cancer Res (2018) 24 (7): 1525–1535.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2451

Published: 02 April 2018

View article

Journal Articles

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer

Eve T. Rodler, Brenda F. Kurland, Melissa Griffin, Julie R. Gralow, Peggy Porter, Rosa F. Yeh, Vijayakrishna K. Gadi, Jamie Guenthoer, Jan H. Beumer, Larissa Korde, Sandra Strychor, Brian F. Kiesel, Hannah M. Linden, John A. Thompson, Elizabeth Swisher, Xiaoyu Chai, Stacie Shepherd, Vincent Giranda, Jennifer M. Specht

Clin Cancer Res (2016) 22 (12): 2855–2864.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-2137

Published: 14 June 2016

View article

Includes: Supplementary data

Journal Articles

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies

Mayer N. Fishman, John A. Thompson, Gregory K. Pennock, Rene Gonzalez, Luz M. Diez, Adil I. Daud, Jeffery S. Weber, Bee Y. Huang, Shamay Tang, Peter R. Rhode, Hing C. Wong

Clin Cancer Res (2011) 17 (24): 7765–7775.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-1817

Published: 18 December 2011

View article

Journal Articles

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Robert J. Amato, Robert E. Hawkins, Howard L. Kaufman, John A. Thompson, Piotr Tomczak, Cezary Szczylik, Mike McDonald, Sarah Eastty, William H. Shingler, Jackie de Belin, Madusha Goonewardena, Stuart Naylor, Richard Harrop

Clin Cancer Res (2010) 16 (22): 5539–5547.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-2082

Published: 14 November 2010

View article

Journal Articles

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

Kazuo Koyanagi, Steven J. O'Day, Peter Boasberg, Michael B. Atkins, He-Jing Wang, Rene Gonzalez, Karl Lewis, John A. Thompson, Clay M. Anderson, Jose Lutzky, Thomas T. Amatruda, Evan Hersh, Jon Richards, Jeffrey S. Weber, Dave S.B. Hoon

Clin Cancer Res (2010) 16 (8): 2402–2408.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-0037

Published: 14 April 2010

View article

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

Jeffrey Weber, John A. Thompson, Omid Hamid, David Minor, Asim Amin, Ilan Ron, Ruggero Ridolfi, Hazem Assi, Anthony Maraveyas, David Berman, Jonathan Siegel, Steven J. O'Day

Clin Cancer Res (2009) 15 (17): 5591–5598.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-1024

Published: 31 August 2009

View article

Includes: Supplementary data

Journal Articles

C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8⁺ Cytotoxic T Cells from Renal Cell Carcinoma Patients

Scott S. Tykodi, Nobuharu Fujii, Nathalie Vigneron, Sharon M. Lu, Jeffrey K. Mito, Maureen X. Miranda, Jeffrey Chou, Lilien N. Voong, John A. Thompson, Brenda M. Sandmaier, Peter Cresswell, Benoît Van den Eynde, Stanley R. Riddell, Edus H. Warren

Clin Cancer Res (2008) 14 (16): 5260–5269.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-0028

Published: 12 August 2008

View article

Includes: Supplementary data

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens

Scott S. Tykodi, Edus H. Warren, John A. Thompson, Stanley R. Riddell, Richard W. Childs, Brith E. Otterud, Mark F. Leppert, Rainer Storb, Brenda M. Sandmaier

Clin Cancer Res (2004) 10 (23): 7799–7811.

DOI: https://doi.org/10.1158/1078-0432.CCR-04-0072

Published: 07 December 2004

View article

Journal Articles

A Phase I Trial of CD3/CD28-activated T Cells (Xcellerated T Cells) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma

John A. Thompson, Robert A. Figlin, Christi Sifri-Steele, Ronald J. Berenson, Mark W. Frohlich

Clin Cancer Res (2003) 9 (10): 3562–3570.

Published: 23 September 2003

View article

Journal Articles

Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma

Alison T. Stopeck, Amanda Jones, Evan M. Hersh, John A. Thompson, Deborah M. Finucane, John C. Gutheil, Rene Gonzalez

Clin Cancer Res (2001) 7 (8): 2285–2291.

Published: 01 August 2001

View article

NARROW

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8⁺ Cytotoxic T Cells from Renal Cell Carcinoma Patients

Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens

A Phase I Trial of CD3/CD28-activated T Cells (Xcellerated T Cells) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma

Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only